XPO1 and B-cell chronic lymphocytic leukemia: These mutations impact cargo binding affinity to XPO1, resulting in altered gene expression, and are validated oncogenic mutations, as the E571 XPO1 mutation has been shown to drive an accelerated rate of leukemogenesis in mouse models of chronic lymphocytic leukaemia (CLL) [40–42].